Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Der Schlüssel zum Erfolg: Könnte sich hier eine 1.000?%-Chance verbergen!?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853260 | ISIN: US4781601046 | Ticker-Symbol: JNJ
Tradegate
15.05.25 | 07:30
131,20 Euro
+0,14 % +0,18
1-Jahres-Chart
JOHNSON & JOHNSON Chart 1 Jahr
5-Tage-Chart
JOHNSON & JOHNSON 5-Tage-Chart
RealtimeGeldBriefZeit
130,86131,1807:37
130,58131,2007:30

Aktuelle News zur JOHNSON & JOHNSON Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiJohnson & Johnson's bladder cancer therapy Balversa accepted by SMC21
Di13 Analysts Have This To Say About Johnson & Johnson50
DiJ&J, Halozyme cut at Leerink on price control risk for combo products45
DiLeerink cuts Johnson & Johnson stock rating on Darzalex concerns56
JOHNSON & JOHNSON Aktie jetzt für 0€ handeln
DiBuy, Sell, Or Hold JNJ Stock At $155?29
MoAbbVie remains king in doctors' perception of immunology drugmakers, but J&J regains some ground33
MoJ&J/Protagonist's icotrokinra shows promise in difficult-to-treat plaque psoriasis6
MoTrump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket65
FrProtagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study5
FrJNJ's Icotrokinra Shows Positive Phase 3 Results In Scalp, Genital Psoriasis614NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) Friday reported positive Phase 3 ICONIC-TOTAL data for Icotrokinra, a once-daily oral peptide that selectively inhibits the IL-23 receptor....
► Artikel lesen
FrJ&J posts promising late-stage data for plaque psoriasis therapy developed with Protagonist7
FrJ&J's skin disease drug meets main goal in late-stage study6
FrJohnson & Johnson reports promising psoriasis drug trial5
FrJohnson & Johnson berichtet über vielversprechende Ergebnisse bei Psoriasis-Medikamententests10
FrJohnson & Johnson: Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis21266% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at...
► Artikel lesen
08.05.J&J Antitrust Trial Heats Up as Innovative Health CEO Testifies on Market Suppression4
08.05.In first oncology expert meeting under Makary, FDA spotlights cancer drugs from J&J, Pfizer, Roche and UroGen67
08.05.Johnson & Johnson Declines on Efforts to Support Nursing4
08.05.ACTO Technologies, Inc.: ACTO APPOINTS FORMER J&J PRESIDENT TO ITS BOARD OF DIRECTORS264Lori Tierney Brings Vast Expertise and Experience to Help ACTO Lead the Life Sciences Industry Towards an AI-First Future TORONTO and NEW YORK, May 8, 2025 /PRNewswire/ -- ACTO, the...
► Artikel lesen
07.05.J&J survey finds pace of oncology innovation is overwhelming physicians4
Seite:  Weiter >>
815 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
7,1,15